Source: International Congress 2018 – Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. Chernokhaeva (St.-petersburg, Russian Federation), M. Pavlova (St.-petersburg, Russian Federation), A. Starshinova (St.-petersburg, Russian Federation), N. Sapozhnikova (St.-petersburg, Russian Federation), L. Archakova (St.-petersburg, Russian Federation), E. Istomina (St.-petersburg, Russian Federation), E. Ershova (St.-petersburg, Russian Federation). Long-term results of multidrug-resistant tuberculosis treatment.. 3674

Member's Comments

No comment yet.

Related content which might interest you: Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Long-term results of drug resistant tuberculosis treatment Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Source: Eur Respir J 2013; 41: 1393-1400 Year: 2013 Treatment results of multidrug-resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013 Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 380s Year: 2006 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011